Table 1. Characteristics of the studies included in the meta-analysis.
| Study | Number of patientsa | Age of biopsy (yr)a | Male(%)a | DCD(%)a | DGF(%)a | Time to AR (month)a | Follow-up (yr)a | Patients | Definition of CD 20 positive/negativea |
|---|---|---|---|---|---|---|---|---|---|
| Bagnasco et al . 2007 | 28/28 | 49 /44 | 75.0/60.7 | NA | 32.1/46.4 | 2.7/2.5 | at least 4yr | first year ACR I-II(Banff 97) | ≥100/HPF /<50/HPF |
| Hippen et al. 2005 | 6/21 | 40 /41 | 66.7/61.9 | 83.3/66.7 | 100.0/100.0 | 4.1/6.1 | at least 4yr | first year ACR IA-IB(Banff 97) | strong and diffuse/trace or rare |
| Hwang et al. 2010 | 23/31 | 37 /40 | 69.6/48.4 | 4.3/22.6 | 8.7/12.9 | NA | 3.6/4.2 | first time ACR I-II(Banff 97) | ≥275/HPF /<100/HPF |
| Sarwal et al. 2003 | 9/22 | NA | NA | NA | NA | NA | NA | ACR | ≥275/HPF /<100/HPF |
| Zarkhin et al. 2008 | 17/15 | 14.5 /13 | 47.1/33.3 | 23.5/26.7 | NA | 51.9/26.1 | 5.8/5.2 | AR | ≥275/HPF /<100/HPF |
DCD: deceased donor; DGF: delayed graft function; HPF: high power field; ACR: acute cellular rejection; AR: acute rejection; NA, not available
a: CD 20 positive group/CD 20 negative group